Enovis (NYSE:ENOV) Releases Earnings Results, Beats Estimates By $0.06 EPS

Enovis (NYSE:ENOV) announced its quarterly earnings data on Wednesday. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.06, Zacks reports. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. Enovis updated its FY 2025 guidance to 3.100-3.250 EPS.

Enovis Stock Down 2.2 %

Shares of NYSE:ENOV traded down $0.93 during midday trading on Wednesday, reaching $41.17. The company’s stock had a trading volume of 512,778 shares, compared to its average volume of 946,080. Enovis has a 12-month low of $38.27 and a 12-month high of $63.96. The firm has a market capitalization of $2.34 billion, a P/E ratio of -18.84 and a beta of 1.94. The firm has a 50 day moving average of $44.96 and a 200-day moving average of $44.37. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40.

Analysts Set New Price Targets

Separately, Needham & Company LLC reiterated a “buy” rating and set a $65.00 price target on shares of Enovis in a research report on Thursday, November 7th.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.